Form 4: KALA Bio CEO Mark Iwicki Sells Shares to Cover Tax Obligations

KALA Bio's CEO, Mark Iwicki, sold 7,392 shares of common stock on May 31, 2024, to cover tax withholding obligations related to vested restricted stock units.

Summary

• Mark Iwicki, CEO of KALA Bio, Inc., reported a transaction on May 31, 2024, involving the sale of 7,392 shares of common stock.
• The sale was executed at a weighted average price of $6.09 per share, with individual transactions ranging from $6.07 to $6.58.
• This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on November 9, 2020.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting and settlement of restricted stock units (RSUs) granted on May 31, 2023.
• Following the reported transaction, Iwicki still beneficially owns 278,923 shares, which includes 244,256 unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing is a routine disclosure of a stock sale under a pre-existing plan to cover tax obligations. It doesn't indicate any fundamental change in the company's prospects.

Positives

• The CEO's stock sale was pre-planned under a 10b5-1 trading plan, indicating transparency and avoiding concerns about insider trading based on current non-public information.

Future Outlook

There is no future outlook provided in this document.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in trading activities by company insiders. This particular filing relates to the CEO's sale of shares to cover tax obligations, which is a common practice.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares, but the pre-planned nature of the sale mitigates concerns about insider trading.

Key Dates